Anebulo Pharmaceuticals Names Biotechnology Industry Executive Simon Allen as CEO and Director

Author's Avatar
Jan 04, 2022

Anebulo Pharmaceuticals, Inc.(Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, has named Simon Allen as Chief Executive Officer and a member of the company’s Board of Directors, effective February 1st, 2022. Mr. Allen succeeds Daniel Schneeberger, MD, who has resigned as CEO and as a Director as of that same date.